From the Shoulders of a Giant

Premium

Looks like Shimadzu wants to join in the proteomics games. The company just spun out Shimadzu Biotech, headquartered in Kyoto, Japan, and led by its former head of life sciences, Tetsuo Ichikawa. The spinoff is “not a single corporation but a strategic global unit,” Ichikawa says; it will draw on the parent company’s subsidiaries in the US, Europe, and Australia. Shimadzu Biotech inherits a $43 million business in bioscience and expects that to grow to more than $170 million within three years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.